Literature DB >> 10935994

Resistance of recent measles virus wild-type isolates to antibody-mediated neutralization by vaccinees with antibody.

M Klingele1, H K Hartter, F Adu, W Ammerlaan, W Ikusika, C P Muller.   

Abstract

The neutralization capacity of sera from Luxembourgian adolescent vaccinees and from Nigerian women with measles-induced immunity to a number of measles virus strains was compared. Although both cohorts were matched for their hemagglutination inhibition and standard neutralization titers, 12 of the 22 late convalescent sera, and only 6 of 24 vaccinees neutralized all viruses. Similarly, only 2 of 20 viruses were not neutralized by at least 75% of late convalescent sera, in comparison to 10 of 20 viruses that resisted neutralization by at least 75% of the vaccinees. The more resistant viruses were not limited to a certain clade. One Nigerian virus was resistant to neutralization by 30% of the late convalescent women and by 75% of vaccinees. These results suggest that qualitative differences in neutralizing antibodies may reduce further protection of infants by passively acquired immunity against wild-type viruses when vaccinated girls become mothers. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10935994     DOI: 10.1002/1096-9071(200009)62:1<91::aid-jmv14>3.0.co;2-b

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization.

Authors:  Rik L de Swart; Selma Yüksel; Albert D M E Osterhaus
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 2.  Review of the temporal and geographical distribution of measles virus genotypes in the prevaccine and postvaccine eras.

Authors:  Michaela A Riddell; Jennifer S Rota; Paul A Rota
Journal:  Virol J       Date:  2005-11-22       Impact factor: 4.099

Review 3.  Measles, the need for a paradigm shift.

Authors:  Emilie Javelle; Philippe Colson; Philippe Parola; Didier Raoult
Journal:  Eur J Epidemiol       Date:  2019-10-17       Impact factor: 8.082

4.  Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups.

Authors:  Masae Itoh; Yoshinobu Okuno; Hak Hotta
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

5.  Antigenic Drift Defines a New D4 Subgenotype of Measles Virus.

Authors:  Miguel Ángel Muñoz-Alía; Claude P Muller; Stephen J Russell
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

6.  HLA-DR specific monoclonal antibodies block lymphoproliferative response to measles vaccine in vitro: a pilot study.

Authors:  David M Phelan; Gregory A Poland
Journal:  Vaccine       Date:  2012-08-31       Impact factor: 3.641

7.  Co-detection of the measles vaccine and wild-type virus by real-time PCR: public health laboratory protocol.

Authors:  Kamelia R Stanoeva; Robert H G Kohl; Rogier Bodewes
Journal:  Access Microbiol       Date:  2021-11-05

8.  Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies.

Authors:  Patrycja J Lech; Gregory J Tobin; Ruth Bushnell; Emily Gutschenritter; Linh D Pham; Rebecca Nace; Els Verhoeyen; François-Loïc Cosset; Claude P Muller; Stephen J Russell; Peter L Nara
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

9.  Mutations in the H, F, or M Proteins Can Facilitate Resistance of Measles Virus to Neutralizing Human Anti-MV Sera.

Authors:  Hasan Kweder; Michelle Ainouze; Sara Louise Cosby; Claude P Muller; Camille Lévy; Els Verhoeyen; François-Loïc Cosset; Evelyne Manet; Robin Buckland
Journal:  Adv Virol       Date:  2014-02-04

Review 10.  Constraints on the Genetic and Antigenic Variability of Measles Virus.

Authors:  Shannon M Beaty; Benhur Lee
Journal:  Viruses       Date:  2016-04-21       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.